Clinical trials: Metastatic Non-small Cell Lung Cancer
Locally Advanced or Metastatic NSCLC
A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
HS-10504 is a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR C797S mutation.
- Trial name
- NCT06461156
- Testing
- HS-10504
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumor (Phase I), Ovarian Cancer
A Study to Evaluate YF550 in Participants With Locally Advanced or Metastatic Solid Tumors.
This study is a open-label, multicenter clinical trials. The target population is participants with locally advanced or metastatic solid tumors. A total of 204 participants are planned to be included.
- Conditions
- Solid Tumor (Phase I), Ovarian Cancer, NSCLC (Advanced Non-small Cell Lung Cancer), TNBC - Triple-Negative Breast Cancer
- Trial name
- NCT07894874
- Testing
- YF550
- Volunteers
- 204 people
- Sponsor
- InventisBio Yiqi Beijing Limited
Triple Negative Breast Cancer, Non-small Cell Lung Cancer
A Biomarker Screening Protocol for Participants With Solid Tumors
Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease…
- Conditions
- Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
- Trial name
- START (NCT05891197)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lyell Immunopharma, Inc.
EGFR Mutation-positive Inoperable or Reccrent NSCLC
Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)
Secondary data collection study: safety and efficacy of VIZIMPRO under Japanese medical practice
- Trial name
- NCT04155541
- Testing
- dacomitinib hydrate
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Pfizer
Carcinoma, Non-Small Cell Lung
CPG 7909 Injection in Non-Small Cell Lung Cancer
Eligible patients will be randomized in a ratio of 2:1 to receive either chemotherapy (a taxane and a platinum compound) plus CPG 7909 Injection or chemotherapy alone.
- Trial name
- NCT00070629
- Testing
- CPG 7909, Chemotherapy
- Where
- 24 sites in United States, Canada and 1 more
- Volunteers
- 116 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer, Advanced Solid Tumors
A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors
This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Combination With Other Anti-cancer Therapies in patients with KRAS G12C mutation advanced or metastatic solid…
- Trial name
- NCT06594874
- Testing
- HS-10370, Adebrelimab, Cisplatin
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
This open-label, single-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) in patients with locally advanced or metastatic non-small cell lung cancer who have completed 4 cycles of standard platinum-based…
- Trial name
- NCT01230710
- Testing
- Erlotinib
- Where
- 7 sites in India
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
The aim of the study is to evaluate the efficacy and safety of SKB264 in combination with osimertinib as first-Line treatment for patients with epidermal growth factor receptor (EGFR) mutations, locally advanced or metastatic…
- Trial name
- NCT06670196
- Testing
- SKB264, Osimertinib
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Lung Cancer, Non-squamous, Non-small Cell
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including…
- Trial name
- NCT06151574
- Testing
- zongertinib, pembrolizumab, cisplatin
- Where
- 163 sites in United States, Argentina and 24 more
- Volunteers
- 428 people
- Sponsor
- Boehringer Ingelheim
Locally Advanced or Metastatic Solid Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1.
- Trial name
- NCT05194982
- Testing
- BL-B01D1
- Where
- 8 sites in China
- Volunteers
- 570 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer Metastatic
Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
The purpose of this research study is to compare the effectiveness and safety of ABP 215 against bevacizumab in men and women with advanced non-small cell lung cancer.
- Trial name
- NCT01966003
- Testing
- Carboplatin, Paclitaxel, ABP 215
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 642 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer, Urothelial Cancer
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum…
- Trial name
- NCT03472560
- Testing
- Avelumab (MSB0010718C), Axitinib (AG-013736)
- Where
- 39 sites in United States, Hungary and 6 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer
SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）
This study was an open-label, multi-center, randomized phase III study to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart versus Immunotherapy+ Platinum-based chemotherapy as First-Line treatment for…
- Trial name
- NCT07633873
- Testing
- SYS6010 injection, Enlonstobart injection, Tislelizumab injection
- Volunteers
- 500 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Locally Advanced or Metastatic Solid Tumors
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2…
- Trial name
- NCT03150810
- Testing
- Pamiparib, Temozolomide
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 139 people
- Sponsor
- BeiGene
Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
This study is an open-label, multicenter Phase II trial, planning to enroll 200 subjects, using BEBT-109 capsules as monotherapy, aimed at evaluating the efficacy and safety of BEBT-109 capsules in subjects with Epidermal Growth…
- Trial name
- NCT06706713
- Testing
- BEBT-109 Capsule
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- BeBetter Med Inc
EGFR Overexpression, Locally Advanced Solid Tumor
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
This is a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can…
- Conditions
- EGFR Overexpression, Locally Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT06975410
- Testing
- YH32364
- Where
- 4 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yuhan Corporation
Non-Small Cell Lung Cancer
Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
This randomized phase 2 trial is studying the effect of adding denosumab to standard chemotherapy in the treatment of advanced lung cancer.
- Trial name
- NCT01951586
- Testing
- Denosumab, Zoledronic acid, Standard Chemotherapy
- Where
- 74 sites in United States, Australia and 8 more
- Volunteers
- 226 people
- Sponsor
- Amgen
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Temozolomide for Treatment of Brain Metastases From Non-Small Cell Lung Cancer (Study P03247)
The purpose of this study is to demonstrate improvement in overall survival for the combination of whole brain radiation therapy (WBRT) plus temozolomide (TMZ) versus WBRT alone.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Brain Neoplasms
- Trial name
- NCT00076856
- Testing
- Temozolomide
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC
Non Small Cell Lung Cancer (NSCLC)
Osimertinib Study in Indian Patients
This is a prospective, single-arm, multicenter, phase-IV study investigating the safety of osimertinib in Indian adult patients.
- Trial name
- NCT03853551
- Testing
- Osimertinib
- Where
- 7 sites in India
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Solid Tumor, Adult
Study of DF1001 in Patients With Advanced Solid Tumors
DF1001-001 is a study of a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases.
- Trial name
- NCT04143711
- Testing
- DF1001, Nivolumab, Nab paclitaxel
- Where
- 44 sites in United States, Belgium and 4 more
- Volunteers
- 270 people
- Sponsor
- Dragonfly Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.